Cargando…

Perception of the COVID-19 Pandemic Among Patients With Inflammatory Bowel Disease in the Time of Telemedicine: Cross-Sectional Questionnaire Study

BACKGROUND: After the COVID-19 outbreak, the Italian Government stopped most regular health care activity. As a result, patients with inflammatory bowel disease (IBD) had limited access to outpatient clinics and hospitals. OBJECTIVE: This study aimed to analyze the perception of the COVID-19 emergen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zingone, Fabiana, Siniscalchi, Monica, Savarino, Edoardo Vincenzo, Barberio, Brigida, Cingolani, Linda, D'Incà, Renata, De Filippo, Francesca Romana, Camera, Silvia, Ciacci, Carolina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JMIR Publications 2020
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654503/ https://www.ncbi.nlm.nih.gov/pubmed/33006945 http://dx.doi.org/10.2196/19574

Ejemplares similares

COVID-19 pandemic perception in adults with celiac disease: an impulse to implement the use of telemedicine
por: Siniscalchi, Monica, et al.
Publicado: (2020)

A Survey on Nutritional Knowledge in Coeliac Disease Compared to Inflammatory Bowel Diseases Patients and Healthy Subjects
por: Marsilio, Ilaria, et al.
Publicado: (2020)

Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study
por: Massimi, Davide, et al.
Publicado: (2021)

Telemedicine in the COVID-19 era for Liver Transplant Recipients: an Italian lockdown area experience
por: Santonicola, Antonella, et al.
Publicado: (2021)

Good efficacy and safety of vedolizumab in Crohn’s disease and ulcerative colitis in a real-world scenario
por: Zingone, Fabiana, et al.
Publicado: (2020)

The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Is It Really a Problem?
por: Barberio, Brigida, et al.
Publicado: (2021)

Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study
por: Barberio, Brigida, et al.
Publicado: (2020)

Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
por: Cingolani, Linda, et al.
Publicado: (2021)

Faecal microbiota transplantation in Clostridioides difficile infection: real-life experience from an academic Italian hospital
por: Barberio, Brigida, et al.
Publicado: (2020)

Serum Levels of PCSK9 Are Increased in Patients With Active Ulcerative Colitis Representing a Potential Biomarker of Disease Activity: A Cross-sectional Study
por: Marinelli, Carla, et al.
Publicado: (2022)

Azathioprine monotherapy withdrawal in inflammatory bowel diseases: A retrospective mono-centric study
por: Crepaldi, Martina, et al.
Publicado: (2023)

Clinical and Psychological Impact of COVID-19 Infection in Adult Patients with Eosinophilic Gastrointestinal Disorders during the SARS-CoV-2 Outbreak
por: Savarino, Edoardo Vincenzo, et al.
Publicado: (2020)

Efficacy of teduglutide in a patient with Crohn’s disease and short bowel syndrome on enteral nutrition: let’s start to think out of the box
por: Barberio, Brigida, et al.
Publicado: (2019)

Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak
por: Zingone, Fabiana, et al.
Publicado: (2020)

Reorganization of the functional gastrointestinal disorders unit during the SARS-CoV-2 outbreak - Practical Recommendations
por: Ghisa, Matteo, et al.
Publicado: (2020)

Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation
por: Barberio, Brigida, et al.
Publicado: (2022)

Lack of complications in patients with eosinophilic gastrointestinal diseases during SARS-CoV-2 outbreak
por: Savarino, Edoardo, et al.
Publicado: (2020)

Factors Influencing Disability and Quality of Life during Treatment: A Cross-Sectional Study on IBD Patients
por: Marinelli, Carla, et al.
Publicado: (2019)

Sleep disturbance in Inflammatory Bowel Disease: prevalence and risk factors – A cross-sectional study
por: Marinelli, C., et al.
Publicado: (2020)

The Lyon Consensus: Does It Differ From the Previous Ones?
por: Ghisa, Matteo, et al.
Publicado: (2020)

Should Patients With Inflammatory Bowel Disease Be Tested for Active COVID-19 Before Starting a Biological Treatment?
por: Barberio, Brigida, et al.
Publicado: (2021)

The Celiac Disease Patients' Ability to Experience Pleasure
por: Zingone, Fabiana, et al.
Publicado: (2019)

Medical and gastroenterological education during the COVID-19 outbreak
por: Barberio, Brigida, et al.
Publicado: (2020)

Sarcopenia, severe anxiety and increased C-reactive protein are associated with severe fatigue in patients with inflammatory bowel diseases
por: Tasson, Laura, et al.
Publicado: (2021)

Reply to comment: Asymptomatic screening for SARS COV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice
por: Zingone, Fabiana, et al.
Publicado: (2020)

Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data
por: Marabotto, Elisa, et al.
Publicado: (2020)

AF.48 COMPARATIVE ASSESSMENT OF ADALIMUMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Marsilio, I., et al.
Publicado: (2021)

A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study
por: Barberio, Brigida, et al.
Publicado: (2021)

Life Events and the Onset of Celiac Disease from a Patient’s Perspective
por: Ciacci, Carolina, et al.
Publicado: (2013)

The Risk of Malignancies in Celiac Disease—A Literature Review
por: Pelizzaro, Filippo, et al.
Publicado: (2021)

Hospitalisation for Drug Infusion Did Not Increase Levels of Anxiety and the Risk of Disease Relapse in Patients with Inflammatory Bowel Disease during COVID-19 Outbreak
por: Bertani, Lorenzo, et al.
Publicado: (2021)

Screening for active COVID-19 infection and immunization status prior to biologic therapy in IBD patients at the time of the pandemic outbreak
por: Zingone, Fabiana, et al.
Publicado: (2020)

Efficacy and safety of oral beclomethasone dipropionate and budesonide MMX versus 5-aminosalicylates or placebo in ulcerative colitis: a systematic review and meta-analysis
por: Barberio, Brigida, et al.
Publicado: (2023)

Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut
por: Michielan, Andrea, et al.
Publicado: (2015)

Extraintestinal Cancers in Inflammatory Bowel Disease: A Literature Review
por: Massano, Alessandro, et al.
Publicado: (2023)

Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease
por: Facchin, Sonia, et al.
Publicado: (2020)

Immunolocalization of leptin and leptin receptor in colorectal mucosa of ulcerative colitis, Crohn’s disease and control subjects with no inflammatory bowel disease
por: Merigo, Flavia, et al.
Publicado: (2020)

Gluten Immunogenic Peptides (GIP) Point-of-Care Urine Test in Coeliac Disease Follow-up before and during the COVID-19 Lockdown in Italy
por: Ciacci, Carolina, et al.
Publicado: (2021)

Commentary on the article: Are hepatitis B virus and celiac disease linked?: HBV and celiac disease
por: Zingone, Fabiana, et al.
Publicado: (2011)

The Perceived Social Burden in Celiac Disease
por: Ciacci, Carolina, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tkbrjasgtu4e0pf3bdbhoghu0t